Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 8/20 | 0.49 |
| ▸ | LGALS9 | O00182 | 4/20 | 0.49 |
| ▸ | LGALS1 | P09382 | 4/20 | 0.49 |
| ▸ | LGALS7; LGALS7B | P47929 | 3/20 | 0.49 |
| ▸ | LGALS4 | P56470 | 4/20 | 0.48 |
| ▸ | SELP | P16109 | 8/20 | 0.45 |
| ▸ | LGALS8 | O00214 | 3/20 | 0.45 |
| ▸ | SELE | P16581 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17773535 | 0.84 | LGALS3 (0.60) | LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS4 | |
| SCHEMBL16642278 | 0.82 | LGALS3 (0.42) | LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS4 | |
| SCHEMBL16642282 | 0.82 | LGALS3 (0.46) | LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS4 | |
| SCHEMBL13658755 | 0.82 | LGALS3 (0.55) | LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS4 | |
| SCHEMBL26491372 | 0.82 | LGALS3 (0.49) | LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS4 | |
| SCHEMBL11371729 | 0.81 | LGALS3 (0.60) | LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS4 | |
| SCHEMBL11368063 | 0.81 | LGALS3 (0.60) | LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS4 | |
| SCHEMBL18385954 | 0.81 | USP2 (0.42) | LGALS3LGALS9LGALS1LGALS7; LGALS7BSELP | |
| SCHEMBL18385953 | 0.80 | SELP (0.42) | LGALS3LGALS9LGALS1LGALS7; LGALS7BSELP | |
| SCHEMBL12886326 | 0.80 | LGALS3 (0.62) | LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150105543-A1 | SYNTHESIS | ONCOLOGY RESEARCH INTERNATIONAL LIMITED (AU) | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105543-A1 | SYNTHESIS | CYP17A1, CYP21A2, CYP11A1 | LGALS3 1319/4885LGALS9 2974/4885LGALS1 2118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.